NEW YORK, Aug. 9, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
The Pain Market Outlook to 2016
http://www.reportlinker.com/p0591017/The-Pain-Market-Outlook-to-2016.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication
Introduction
The heterogeneity of pain necessitates a wide range of analgesics with different modes of action and delivery methods. As such, many different classes of drugs co-exist in the pain market. However, despite the wide range of treatment options, pain remains inadequately managed and substantial market opportunities exist for developers in chronic pain and neuropathic pain.
Features and benefits
* Assess the forecast epidemiology and development of the pain market across the 7MM.
* Analyze the dynamics of the global pain market and understand the impact of key R&D events, market trends, and issues.
* Gain up-to-date competitive intelligence and understand the major issues affecting key pharmaceutical marketers and product development.
* Forecast revenues for major currently marketed and pipeline pain products over 2010–16
* Develop strategies for success in the future global pain market.
Highlights
The global pain market recorded sales of $22.0bn in 2010, rising at a compound annual growth rate (CAGR) of 8.9% from 2005. This growth was supported by the presence of five blockbuster pain drugs - OxyContin, Lyrica, Cymbalta, Celebrex and Lidoderm. However, as patent expiries loom, the global market value is set to contract to $18.7bn by 2016.
The pain pipeline is vast, featuring over 200 drugs in clinical development. Chronic pain remains the most studied indication, although there remains strong interest in neuropathic pain and acute pain. Tapentadol ER has the greatest potential of any pipeline drug, with superior tolerability to OxyContin and potential efficacy in neuropathic pain.
Pfizer was the market-leading company in the global pain market, registering $6.4bn in sales in 2010. Collectively, the top five pain companies accounted for 76.1% of the global market. This dominance is set to wane as their pipelines will be unable to restore market share lost to generics and new product launches.
Your key questions answered
* What are the drivers and resistors of the pain market worldwide?
* What market and pipeline developments are shaping the strategies of leading pharmaceutical companies in the pain market?
* What is the commercial potential of the most promising compounds in clinical development?
* Who were the leading players in the global pain market in 2010?
Executive Summary
Overview of health technology assessment
National HTA organizations profiled
HTA in practice
Influence of HTA on pricing and reimbursement
Industry's role in HTA
Future perspectives
About the author
Disclaimer
Overview of health technology assessment
Summary
Introduction
Definition of HTA
HTA processes
Evolution of HTA
Collaborative initiatives
INAHTA
HTAi
EuroScan
EUnetHTA
Key HTA principles
Influence of HTA on pharma/medtech
National HTA organizations profiled
Summary
Introduction
Australia
PBAC
MSAC
PLAC
Canada
CADTH
Provincial HTA organizations
France
Pharmaceutical HTA
Medical device HTA
MTAs
Germany
G-BA
IQWiG
DAHTA@DIMDI
UK
NICE technology appraisals
Evaluation Pathway Program
NIHR HTA
US
CMS
AHRQ
PCORI
DERP
Private sector
HTA in practice
Summary
Introduction
Transparency
Stakeholder involvement
Patient input
Canada's new process for CDR
Calculating cost-effectiveness
NICE threshold
Theoretical thresholds
Cost minimization
Efficiency frontier
Cost-consequence analysis
Timeliness of HTA
Influence of HTA on pricing and reimbursement
Summary
Introduction
Uptake of HTA advice by payors
Australian government overrides PBAC advice
Listing of drugs assessed centrally in Canada
Dual recommendations in France
Pharmaceuticals
Medical devices
Reassessment
Germany's new early assessment procedure
HTA of older products
Implementation of advice by providers
Future role of NICE
Changing US landscape
CMS coverage of Provenge
Tackling uncertainty
US CED
Ontario's cancer drug scheme
UK patient access schemes
Managed entry in Australia
Industry's role in HTA
Summary
Introduction
European Tapestry Network
Swiss HTA consensus
Industry case study
Industry relationship with payors/policy-makers
Regulator/HTA/payor interaction
UK pilot parallel scientific advice process
Sweden's experience with parallel advice
US collaboration
Future perspectives
Summary
Introduction
Increased scope of HTA
Orphan drugs
HTA as part of product development
HTA and market access schemes
Convergence of HTA programs
EU HTA co-operation
Relative effectiveness/comparative effectiveness
Summary of conclusions
Appendix
Scope
Methodology
Secondary research
Glossary/Abbreviations
To order this report:
Drug and Medication Industry: The Pain Market Outlook to 2016
Drug and Medication Business News
Check our Company Profile, SWOT and Revenue Analysis!
Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
Share this article